Impact on enamel and dentine hypersensitivity through mediated impact of antagonists on TRPV1 and TRCP5 channels in oral care products
A combination of galangin, oleic acid, and adenosine in oral care products effectively targets TRPV1 and TRPC5 receptors to address dental hypersensitivity, achieving substantial and lasting pain relief by modulating neural activity.
Patent Information
- Application Number
- PCT/EP2025/053032
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-12
- Filing Date
- 2025-02-06
- Publication Date
- 2025-08-21
AI Technical Summary
Current treatments for dental enamel and dentine hypersensitivity, such as potassium salts and resin varnishes, are ineffective and often cause irritation, as they primarily focus on occluding dentine tubules without addressing the underlying neurochemical mechanisms of pain perception, leading to temporary relief that may be compromised by dental caries progression.
A combination of galangin, oleic acid, and adenosine is used in oral care products to inhibit TRPV1 and TRPC5 receptors, providing long-lasting sensitivity reduction by modulating neural activity and blocking pain signals.
The combination significantly decreases dental and periodontal tissue sensitivity by an average of 66% after the first application, offering prolonged pain relief without irritation, as demonstrated in a randomized controlled study.